Seminars in thoracic and cardiovascular surgery
-
Semin. Thorac. Cardiovasc. Surg. · Jan 2005
Review Comparative StudyAnticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia.
Unfractionated heparin (UFH) is the gold standard for anticoagulation during cardiopulmonary bypass (CPB). Of patients undergoing CPB operations, 25% to 50% develop heparin-dependent antibodies during the postoperative period, typically between day 5 and 10, if UFH is continued during the postoperative course. ⋯ If urgent cardiac operation with the use of CPB in patients with positive antibody titer is required, different anticoagulatory approaches are available, such as lepirudin, bivalirudin, and danaparoid or UFH in combination with platelet antagonists, such as epoprostenol or tirofiban. In patients with previous HIT but no detectable antibodies, UFH alone can be used only during CPB, but alternative anticoagulation has to be used pre- and postoperatively.
-
Semin. Thorac. Cardiovasc. Surg. · Jan 2005
Review Comparative StudyCardiac surgery in patients on antiplatelet and antithrombotic agents.
The widespread application of antithrombotic agents carries significant potential for inducing excessive peri-operative hemorrhage during cardiac surgery. Specific surgical and medical strategies can be employed to attenuate this bleeding. These antithrombotic agents and anti-hemorrhagic measures will be reviewed in depth.
-
Semin. Thorac. Cardiovasc. Surg. · Jan 2005
ReviewAnesthesia and neurocerebral monitoring for aortic dissection.
Patients presenting to the operating room for repair of aortic dissection are challenging in all aspects of their care. Without exception, they require a multidisciplinary team approach. This article will review some of the specific challenges faced by anesthesiologists and neurologists when confronted with such a diagnosis. ⋯ Neurologic complications during dissection repair result in increased morbidity and mortality. A variety of neurophysiologic monitoring techniques exist that may reduce this risk and will be discussed in detail. Finally, we will present some "controversies in care," emphasizing that our respective fields continue to grow, learn, and improve what information we have on the morbidity and mortality of aortic dissection.
-
Semin. Thorac. Cardiovasc. Surg. · Jan 2005
ReviewAcute descending aortic dissections: management of visceral, spinal cord, and extremity malperfusion.
Acute descending aortic dissection is considered the most catastrophic event affecting the aorta and occurs two to three times more often than rupture of abdominal aortic aneurysms. The therapeutic aim in treating acute dissection is not only directed at the prevention of aneurysmal development and rupture but also to prevent and treat complications such as malperfusion syndrome. According to Lauterbach and coworkers patients with symptomatic malperfusion syndromes have a 51% mortality rate compared with a 29% mortality rate in patients who do not. ⋯ Despite an improvement in diagnosing dissections and malperfusion syndromes, and despite improved operative techniques and a better understanding of the significance of perioperative care, the surgical mortality rate can be as high as 50%. Endovascular techniques are constantly evolving that provide an alternative to open procedures. The goal of this article was to review the pathogenesis of malperfusion syndromes in aortic dissection, discuss the current modalities to treat malperfusion of the spinal cord, viscera, and extremities, and examine the results of the treatments used today.
-
As a result of advances in surgical techniques, immunosuppressive therapy, and postoperative management, lung transplantation has become an established therapeutic option for individuals with a variety of end-stage lung diseases. The current 1-year actuarial survival rate following lung transplantation is approximately 75%. However, the processes of acute and chronic lung allograft rejection have limited the long-term success of lung transplantation. ⋯ Indeed, graft rejection, infection, and malignancy are the three principal causes of mortality for the lung transplant recipient. One should also keep in mind that graft loss in a lung transplant recipient is usually a fatal event, since there is no practical means of long-term mechanical support, and since the prospects of re-transplantation are low, given the shortage of acceptable donor grafts. This chapter reviews the current state of immunosuppressive therapy for lung transplantation, and suggests alternative paradigms for the management of future lung transplant recipients.